These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36933565)

  • 21. Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients.
    Kim MK; Lee KS; Ham SY; Choi YY; Lee E; Lee S; Lee B; Jeon J; Chin B; Kim Y; Kim G; Jang HC; Choi JP; Park SW
    J Korean Med Sci; 2023 Sep; 38(35):e272. PubMed ID: 37667578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
    Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
    Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
    Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
    Ioannou GN; Berry K; Rajeevan N; Li Y; Mutalik P; Yan L; Bui D; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Bajema KL
    Ann Intern Med; 2023 Nov; 176(11):1486-1497. PubMed ID: 37903369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.
    Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM
    Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
    Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M
    Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
    Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
    Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 33. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19).
    Li H; Gao M; You H; Zhang P; Pan Y; Li N; Qin L; Wang H; Li D; Li Y; Qiao H; Gu L; Xu S; Guo W; Wang N; Liu C; Gao P; Niu J; Cao J; Zheng Y
    Clin Infect Dis; 2023 Feb; 76(3):e148-e154. PubMed ID: 35870128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
    Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
    BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study.
    Congdon S; Narrowe Z; Yone N; Gunn J; Deng Y; Nori P; Cowman K; Islam M; Rikin S; Starrels J
    Sci Rep; 2023 Nov; 13(1):19688. PubMed ID: 37951998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.
    Rajme-López S; Martinez-Guerra BA; Román-Montes CM; Tamez-Torres KM; Tello-Mercado AC; Tepo-Ponce KM; Segura-Ortíz Z; López-Aguirre A; Gutiérrez-Mazariegos ODR; Lazcano-Delgadillo O; Nares-López R; González-Lara MF; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J; Ponce-de-León A; Ruíz-Palacios GM
    Ther Adv Infect Dis; 2024; 11():20499361241236582. PubMed ID: 38545451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study.
    Chen X; Zhu Y; Shen L; Zhou D; Feng N; Tong Q
    J Intensive Care Med; 2024 Aug; 39(8):742-750. PubMed ID: 38356292
    [No Abstract]   [Full Text] [Related]  

  • 39. Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic.
    Bose-Brill S; Hirabayashi K; Schwimmer E; Pajor NM; Rao S; Mejias A; Jhaveri R; Forrest CB; Bailey LC; Christakis DA; Thacker D; Hanley PC; Patel PB; Cogen JD; Block JP; Prahalad P; Lorman V; Lee GM;
    Hosp Pediatr; 2024 Aug; 14(8):e341-e348. PubMed ID: 39076115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
    Zheng B; Tazare J; Nab L; Green AC; Curtis HJ; Mahalingasivam V; Herrett EL; Costello RE; Eggo RM; Speed V; Bacon SC; Bates C; Parry J; Cockburn J; Hester F; Harper S; Schaffer AL; Hulme WJ; Mehrkar A; Evans SJ; MacKenna B; Goldacre B; Douglas IJ; Tomlinson LA;
    Lancet Reg Health Eur; 2023 Nov; 34():100741. PubMed ID: 37927438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.